Eli Lilly (LLY)
(Delayed Data from NYSE)
$915.04 USD
+10.07 (1.11%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $911.40 -3.64 (-0.40%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
LLY 915.04 +10.07(1.11%)
Will LLY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LLY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LLY
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?
LLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
Tap the Weight-Loss Drug Market With These ETFs
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
Other News for LLY
Tandem Diabetes rises as insulin pump cleared for use in EU with Lilly insulin
Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential
American Century Growth Fund Q2 2024 Commentary
Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO
Vanda slips as FDA rejects therapy for stomach condition